Mustang Bio, Inc. develops clinical-stage cell therapies for difficult-to-treat cancers, with programs centered on CAR T approaches and related oncology technologies. Company updates commonly cover MB-101, an IL13Rα2-targeted CAR T-cell therapy for astrocytomas and glioblastoma, MB-108, an HSV-1 oncolytic virus program, and the combination therapy MB-109.
Recurring news also includes FDA orphan drug designation activity, clinical and preclinical program disclosures, public offerings and warrants, reverse stock split actions, Nasdaq Capital Market listing compliance, and facility or asset changes tied to the company’s operating footprint.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.